日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent models

在啮齿动物模型中,CR4056 与吗啡联合使用比单独使用吗啡具有更好的疗效、耐受性、安全性和滥用倾向

Emanuele Sala, Flora Ferrari, Marco Lanza, Chiara Milia, Chiara Sabatini, Albino Bonazzi, Eleonora Comi, Miriam Borsi Franchini, Gianfranco Caselli, Lucio Claudio Rovati

Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

CR6086(一种强效前列腺素 E2 受体 4 拮抗剂)作为一种新型潜在改善病情的抗风湿药物的药理学特性

Gianfranco Caselli, Albino Bonazzi, Marco Lanza, Flora Ferrari, Daniele Maggioni, Cristian Ferioli, Roberto Giambelli, Eleonora Comi, Silvia Zerbi, Marco Perrella, Ornella Letari, Elena Di Luccio, Milena Colovic, Stefano Persiani, Tiziano Zanelli, Laura Mennuni, Tiziana Piepoli, Lucio Claudio Rovati

Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis

首创的咪唑啉-2 型镇痛药 CR4056 与萘普生在两种骨关节炎大鼠模型中的疗效比较

Eleonora Comi, Marco Lanza, Flora Ferrari, Valeria Mauri, Gianfranco Caselli, Lucio Claudio Rovati

BRCA-associated ovarian cancer: from molecular genetics to risk management

BRCA相关卵巢癌:从分子遗传学到风险管理

Girolimetti, Giulia; Perrone, Anna Myriam; Santini, Donatella; Barbieri, Elena; Guerra, Flora; Ferrari, Simona; Zamagni, Claudio; De Iaco, Pierandrea; Gasparre, Giuseppe; Turchetti, Daniela